EU mulls new Prevnar 13 indication

A greenlight could garner Pfizer $1B in sales.

August 11, 2014

5:53 pm

The EU is mulling an expanded indication for Pfizer’s pneumococcal vaccine Prevnar 13. PM Live reports that expanding the use to include prevention of community-acquired pneumonia among the elderly could mean an additional $1 billion in sales. The drug is already approved for preventing invasive pneumococcal diseases among adults.

The US is set to consider an expanded indication in September, and the US Advisory Committee on Immunization Practices is expected to weigh in sometime this month.

From Our Partners

Living brands: How to build brands in the age of omnichannel

Partner Content

Living brands: How to build brands in the age of omnichannel

This podcast looks at how to leverage advancements in data, technology, AI and content development in order to become a Living Brand.

Partner Content

The new brand.com experience

How healthcare manufacturers can improve customer engagement, drive high-value activity and inform future strategy with conversational AI.

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

Partner Content

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

The Healthcare Marketers Trend Survey shows that, as far as channel usage goes, more growth occurred in newer tactics like non-linear video and streaming audio than in some of the more traditional ones.

A Big C Shift: Rebranding cancer to reflect advances in oncology

Partner Content

A Big C Shift: Rebranding cancer to reflect advances in oncology

Pivoting people’s perception of the disease to match the realities of treatment.